Advertisement
U.S. markets close in 54 minutes
  • S&P 500

    5,257.28
    +8.79 (+0.17%)
     
  • Dow 30

    39,807.43
    +47.35 (+0.12%)
     
  • Nasdaq

    16,394.09
    -5.44 (-0.03%)
     
  • Russell 2000

    2,122.39
    +8.04 (+0.38%)
     
  • Crude Oil

    83.01
    +1.66 (+2.04%)
     
  • Gold

    2,241.10
    +28.40 (+1.28%)
     
  • Silver

    24.95
    +0.20 (+0.82%)
     
  • EUR/USD

    1.0789
    -0.0041 (-0.38%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2620
    -0.0018 (-0.14%)
     
  • USD/JPY

    151.4070
    +0.1610 (+0.11%)
     
  • Bitcoin USD

    70,622.58
    +1,935.02 (+2.82%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Nymox Pharmaceutical Corporation

OKLAHOMA CITY, OK--(Marketwired - Dec 1, 2014) - On November 24, 2014, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Nymox Pharmaceutical Corporation (NASDAQ: NYMX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is January 31, 2011 through November 2, 2014.

Plaintiff seeks to recover damages on behalf of all Nymox Pharmaceutical Corporation shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, January 26, 2015 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:

Advertisement